ArticleJournal of oncology2013
The use of strontium-90 Beta radiotherapy as adjuvant treatment for conjunctival melanoma.
Article in Journal of oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Ruthenium-106 ocular surface brachytherapy for incompletely excised conjunctival melanoma and squamous cell carcinoma.Journal of contemporary brachytherapy · 2026Article
- Emerging Techniques in the Treatment of Conjunctival Melanoma.Current ophthalmology reports · 2025Review
- Yttrium-90 (American journal of ophthalmology case reports · 2024Article
- Adjuvant Brachytherapy with Ruthenium-106 to Reduce the Risk of Recurrence of Conjunctival Melanoma after Excision.Ocular oncology and pathology · 2024Article
- Dosimetric Investigation of Six Ru-106 Eye Plaques by EBT3 Radiochromic Films and Monte Carlo Simulation.Journal of biomedical physics & engineering · 2023Article
- Annulus-shaped I-125 plaque brachytherapy for conjunctival melanoma.American journal of ophthalmology case reports · 2022Article
- Small but Challenging Conjunctival Melanoma: New Insights, Paradigms and Future Perspectives.Cancers · 2021Review
- Current Management of Conjunctival Melanoma Part 2: Treatment and Future Directions.Turkish journal of ophthalmology · 2020Review
- Conjunctival Melanoma with Ipsilateral, Non-Contiguous Eyelid Involvement: A Case Report and Comprehensive Review of the Literature.Ocular oncology and pathology · 2020Article
- Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas.Radiation oncology (London, England) · 2019Article
- Management Issues in Conjunctival Tumours: Conjunctival Melanoma and Primary Acquired Melanosis.Ophthalmology and therapy · 2019Review
- Proton radiotherapy in advanced malignant melanoma of the conjunctiva.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Article
- Effect of Beta Particles Spectrum on Absorbed Fraction in Internal Radiotherapy.Asia Oceania journal of nuclear medicine & biology · 2019Article
- [Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2015Review
- Management of conjunctival malignant melanoma: a review and update.Expert review of ophthalmology · 2014Article
- High-Dose-Rate Yttrium-90 (Ophthalmology scienceArticle
- Yttrium-90 Episcleral Plaque Brachytherapy for Choroidal Melanoma.Journal of vitreoretinal diseasesArticle
- Advances in the management of conjunctival melanoma.Survey of ophthalmologyReview
- Innovations in brachytherapy.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims. To report the safety and efficacy of strontium (Sr(90)) beta radiotherapy as adjuvant treatment for conjunctival melanoma. Methods. A retrospective cohort study was undertaken from 1999 to 2007 of all patients who underwent Sr(90) beta radiotherapy for incompletely excised conjunctival melanoma. Failure of treatment was defined as recurrence of a conjunctival melanoma at the same location following beta radiotherapy. Results. Twenty patients underwent Sr(90) beta radiotherapy for incompletely excised conjunctival melanoma. Median follow-up interval was 59 months (8-152). All patients had conjunctival melanoma involving the bulbar conjunctiva. Underlying diagnoses included PAM with atypia in 60% (12 of 20), PAM without atypia in 15% (3 of 20), and de novo conjunctival melanoma in 25% (5 of 20). Following Sr(90) beta radiotherapy, in 90% (18 out of 20) local control was achieved and visual acuity was not affected in any patient. Three patients (15%) had dry eye symptoms, episcleritis, and descemetcoele, respectively. No cataract or secondary glaucoma was reported. Conclusions. Sr(90) treatment is a very effective adjuvant treatment after excisional biopsy and cryotherapy for conjunctival melanoma with a local success rate of 90%. The treatment is not associated with significant side effects and visual acuity is not affected.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.